Spexis AG Stock price

Equities

POLN

CH0106213793

Pharmaceuticals

Delayed Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
0.085 CHF +13.33% Intraday chart for Spexis AG +10.39% +107.32%
Sales 2021 331 366.87 Sales 2022 1.48M 1.64M Capitalization 19.96M 22.13M
Net income 2021 -11M -12.19M Net income 2022 -18M -19.95M EV / Sales 2021 * -
Net cash position 2021 6.23M 6.91M Net Debt 2022 4.23M 4.69M EV / Sales 2022 16.4 x
P/E ratio 2021 *
-
P/E ratio 2022
-1.07 x
Employees 28
Yield 2021 *
-
Yield 2022
-
Free-Float 46.61%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Spexis AG

1 day+13.33%
1 week+10.39%
Current month-48.48%
1 month-44.63%
3 months+107.32%
6 months-69.86%
Current year+107.32%
More quotes
1 week
0.07
Extreme 0.0702
0.09
1 month
0.07
Extreme 0.07
0.18
Current year
0.04
Extreme 0.0398
1.06
1 year
0.01
Extreme 0.0122
1.06
3 years
0.01
Extreme 0.0122
2.20
5 years
0.01
Extreme 0.0122
2.20
10 years
0.01
Extreme 0.0122
2.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 21-12-29
Director of Finance/CFO - -
Chief Operating Officer 55 21-12-29
Members of the board TitleAgeSince
Director/Board Member 62 21-12-29
Director/Board Member 78 21-12-29
Director/Board Member 68 12-08-31
More insiders
Date Price Change Volume
24-03-28 0.085 +13.33% 198,276
24-03-27 0.075 -2.60% 332,111
24-03-26 0.077 0.00% 31,358
24-03-25 0.077 0.00% 272,226
24-03-22 0.077 0.00% 53,915

Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT

More quotes
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Spexis AG - Swiss Exchange